MedTrace Logo

NOSTRA-Feasibility Study: A Study Looking at Ultrasound Guided Biopsies for Breast Cancer

NCT04118192 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2025-01-24

No results posted yet for this study

Summary

A prospective non-randomised multi-centre feasibility study to assess if patients with residual cancer following dual-targeted neoadjuvant chemotherapy treatment for HER2-positive, ER-negative early breast cancer can be identified by multiple ultrasound (US)-guided tumour bed core biopsies

Conditions

Interventions

PROCEDURE

Tumour bed core biopsy

Collection of up to 8 core biopsies across 4 zones of the whole tumour bed to detect residual cancer post neo-adjuvant treatment

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Cancer Research UK

    collaborator OTHER

  • University of Birmingham

    lead OTHER

Principal Investigators

  • Daniel Rea · University of Birmingham

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-22
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04118192 on ClinicalTrials.gov